APGE FY2025 SEC EDGAR DEF 14A #157 of 168 in industry

Apogee Therapeutics, Inc. CEO pay ratio

The CEO earned $1.4M in FY2025 against median worker pay of $283,326 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
MA
Filing date
2026-04-24
Industry
Chemicals & Pharmaceuticals
Industry rank
#157/168

Data updated August 2026

Subscribe to Apogee Therapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
5:1
Below Average (Scale: 0–1000:1)
CEO pay
$1.4M
Median worker
$283,326

Answer first

Apogee Therapeutics, Inc.'s FY2025 CEO total of $1.4M ranks #1195 of 1,423 complete filings; its 5:1 pay ratio ranks #1362. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $283,326. Industry placement uses the FY2025 SIC-28 peer cohort (# 157 of 168, 7th percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1195
$1.4M of 1,423 FY2025
Ratio rank
#1362
5:1 of 1,423
Industry pct
7th
among the lower quartile of industry peers by pay ratio

How Apogee Therapeutics, Inc. ranks nationally

Apogee Therapeutics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$1,416,630 16th percentile higher than 16% of 1,423 companies

$0–$2,500,000: 304 companies (21%). This entry sits in this band. $2,500,000–$5,000,000: 182 companies (13%). Above this entry. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Apogee Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($1.4M) against pay ratio (5:1) for Apogee Therapeutics, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02072002.94144005.96216008.88288011.82.1:112.5:123:133.4:143.9:1CEO total payPay ratio (CEO : median worker)Apogee Therapeutics, Inc., CEO total pay: 1416630 · Pay ratio (CEO : median worker): 5:1Apogee Therapeutics, Inc.Celanese Corp, CEO total pay: 462700 · Pay ratio (CEO : median worker): 5:1Celanese CorpHighwater Ethanol LLC, CEO total pay: 394644 · Pay ratio (CEO : median worker): 4:1Highwater Ethanol LLCViridian Therapeutics, Inc.\DE, CEO total pay: 6776249 · Pay ratio (CEO : median worker): 4:1Viridian Therapeutics, Inc.\DEAlzamend Neuro, Inc., CEO total pay: 130000 · Pay ratio (CEO : median worker): 6:1Alzamend Neuro, Inc.Edgewise Therapeutics, Inc., CEO total pay: 443614 · Pay ratio (CEO : median worker): 6:1Edgewise Therapeutics, Inc.
Apogee Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Apogee Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
5:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$1.4M
Companies in Industry
168
vs. Industry Median
Below
#157 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Apogee Therapeutics, Inc.: near-parity Item 402(u) ratio

Apogee Therapeutics, Inc.'s FY2025 ratio 5:1 ranks #157 of 168 Chemicals & Pharmaceuticals filers (7th percentile). the CEO earned 5× the median employee ($283,326) in FY2025.

At $283,326 median worker pay, the FLOOR stamp is near pay-parity territory under LIGHT CEO total.

CEO Total Pay

$1.4M

FY2025 Summary Compensation, below median

Pay Ratio

5:1

Below typical

Apogee Therapeutics, Inc. in the lower Chemicals & Pharmaceuticals third

Apogee Therapeutics, Inc.'s FY2025 ratio 5:1 ranks #157 of 168 Chemicals & Pharmaceuticals filers (7th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Apogee Therapeutics, Inc.'s $1.4M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1195 and ratio rank #1362 split - treat 5:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$1.4M
Median Employee Pay
$283,326
Pay Ratio
5:1
Filing Date
2026-04-24

Company Info

Ticker
APGE
CIK
1974640
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
MA
View SEC filings →
SEC EDGAR DEF 14A for CIK 1974640, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Apogee Therapeutics, Inc.'s FY2025 ratio 5:1 ranks #157 of 168 Chemicals & Pharmaceuticals filers (7th percentile).

Read with Apogee Therapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · LIGHT · ELITE-MED.

Gitlab Inc. · LIGHT

ABS(ceo_total_comp) peer at $1.4M (Δ $7K lighter vs Apogee Therapeutics, Inc.); FLOOR · ELITE-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Chemung Financial Corp · LIGHT

ABS(ceo_total_comp) peer at $1.4M (Δ $19K heavier vs Apogee Therapeutics, Inc.); MODEST · PAR-MED vs this page's FLOOR · LIGHT · ELITE-MED.
C & F Financial Corp · LIGHT

ABS(ceo_total_comp) peer at $1.4M (Δ $20K heavier vs Apogee Therapeutics, Inc.); FLOOR · HIGH-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Northrim Bancorp Inc · LIGHT

ABS(ceo_total_comp) peer at $1.4M (Δ $21K lighter vs Apogee Therapeutics, Inc.); FLOOR · HIGH-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Celanese Corp (SIC 28 pole)

Celanese Corp stamps FLOOR · MICRO nearest in-SIC by ABS(pay_ratio) to Apogee Therapeutics, Inc.'s FLOOR filing.
National dual ranks · #1195/#1362

Apogee Therapeutics, Inc.'s FY2025 package sits #1195 by CEO dollars and #1362 by ratio under LIGHT · FLOOR.
Ratio primer · FLOOR

Apogee Therapeutics, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Apogee Therapeutics, Inc. (CIK 1974640), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.